Sugi Predict

Sugi Predict / Compounds / SCHEMBL2261012

SCHEMBL2261012

SCHEMBL2261012

CC(C)N(C(C)C)P(Cl)OCc1ccccc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 3/20 0.39
▸ KMT2A Q03164 2/20 0.37
▸ IDO1 P14902 1/20 0.36
▸ AGXT P21549 1/20 0.35
▸ ALDH1A1 P00352 3/20 0.35
▸ CA1 P00915 1/20 0.35
▸ CA2 P00918 1/20 0.35
▸ CA9 Q16790 1/20 0.35
▸ MAPK1 P28482 2/20 0.35
▸ LMNA P02545 1/20 0.35
▸ HPGD P15428 1/20 0.35
▸ HTT P42858 1/20 0.35
▸ SLC6A2 P23975 2/20 0.34
▸ TAAR1 Q96RJ0 2/20 0.34
▸ MAOA P21397 1/20 0.34
▸ SLC6A4 P31645 1/20 0.34
▸ SLC6A3 Q01959 1/20 0.34
▸ SIGMAR1 Q99720 1/20 0.34
▸ CYP2A6 P11509 1/20 0.34
▸ ADORA2A P29274 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2252915 0.81 TSHR (0.41) TSHRKMT2AIDO1AGXTALDH1A1
SCHEMBL80897 0.81 TSHR (0.41) TSHRKMT2AIDO1AGXTALDH1A1
SCHEMBL2227585 0.80 TSHR (0.40) TSHRKMT2AIDO1AGXTALDH1A1
SCHEMBL2257325 0.79 TSHR (0.43) TSHRIDO1AGXTALDH1A1MAPK1
SCHEMBL24027339 0.79 TSHR (0.39) TSHRKMT2AIDO1AGXTALDH1A1
SCHEMBL2240873 0.79 KMT2A (0.40) TSHRKMT2AIDO1ALDH1A1MAPK1
SCHEMBL24027472 0.76 TSHR (0.36) TSHRKMT2AIDO1AGXTALDH1A1
SCHEMBL5831072 0.74 CA1 (0.33) TSHRKMT2AIDO1ALDH1A1CA1
SCHEMBL1117737 0.74 TSHR (0.55) TSHRKMT2AIDO1AGXTALDH1A1
SCHEMBL5831071 0.73 TSHR (0.32) TSHRKMT2AIDO1ALDH1A1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170210775-A1 GUGGULPHOSPHOLIPID METHODS AND COMPOSITIONS JINA PHARMACEUTICALS, INC. 2017-07-27 — — US claimed
US-9637515-B2 Guggulphospholipid methods and compositions JINA PHARMACEUTICALS, INC. (US) 2017-05-02 — — US claimed
EP-2088865-B1 GUGGULPHOSPHOLIPID METHODS AND COMPOSITIONS JINA PHARMACEUTICALS INC (US) 2015-10-21 — — EP claimed
US-20100151002-A1 Guggulphospholipid Methods and Compositions JINA PHARMACEUTICALS, INC. (US) 2010-06-17 — — US claimed
US-20220195424-A1 Chemical Capping for Template Switching NEW ENGLAND BIOLABS, INC. (US) 2022-06-23 — — US disclosed
WO-2020231697-A1 CHEMICAL CAPPING FOR TEMPLATE SWITCHING NEW ENGLAND BIOLABS, INC. (US) 2020-11-19 — — WO disclosed
US-20170210775-A1 GUGGULPHOSPHOLIPID METHODS AND COMPOSITIONS JINA PHARMACEUTICALS, INC. 2017-07-27 — — US disclosed
US-9637515-B2 Guggulphospholipid methods and compositions JINA PHARMACEUTICALS, INC. (US) 2017-05-02 — — US disclosed
EP-2088865-B1 GUGGULPHOSPHOLIPID METHODS AND COMPOSITIONS JINA PHARMACEUTICALS INC (US) 2015-10-21 — — EP disclosed
US-7994152-B2 Method of treating a cancer by administering A 2′,5′-oligoadenylate analog SANKYO COMPANY, LIMITED (JP) 2011-08-09 — — US disclosed
US-20100323000-A1 METHOD AND PROCESS FOR PREPARING CARDIOLIPIN NEOPHARM, INC. (US) 2010-12-23 — — US disclosed
US-20100151002-A1 Guggulphospholipid Methods and Compositions JINA PHARMACEUTICALS, INC. (US) 2010-06-17 — — US disclosed
US-20100035976-A1 Method of treating a tumor or a viral disease by administering a 2' , 5' -oligoadenylate analog SANKYO COMPANY, LIMITED (JP) 2010-02-11 — — US disclosed
US-7651999-B2 phosphorothioate modification containg oligonadenylates useful as antiviral, anticarcinogenic and antitumor agent; stable and have superior activity for treating lung cancer SANKYO COMPANY, LIMITED (JP) 2010-01-26 — — US disclosed
EP-2088865-A2 GUGGULPHOSPHOLIPID METHODS AND COMPOSITIONS Jina Pharmaceuticals Inc. (US) 2009-08-19 — — EP disclosed
WO-2008058156-A9 GUGGULPHOSPHOLIPID METHODS AND COMPOSITIONS JINA PHARMACEUTICALS INC (US) 2008-12-04 — — WO disclosed
WO-2008058156-A2 GUGGULPHOSPHOLIPID METHODS AND COMPOSITIONS JINA PHARMACEUTICALS INC. (US) 2008-05-15 — — WO disclosed
US-20050266068-A1 Cardiolipin molecules and methods of synthesis NEOPHARM, INC. (US) 2005-12-01 — — US disclosed
US-20050261235-A1 2' ,5' -Oligoadenylate analogs SANKYO COMPANY, LIMITED (JP) 2005-11-24 — — US disclosed
EP-1568704-A1 NOVEL 2' ,5' -OLIGOADENYLIC ACID ANALOGUES Sankyo Company, Limited (JP) 2005-08-31 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050261235-A1 2' ,5' -Oligoadenylate analogs NSUN2, RNGTT, NSUN3 TSHR 1870/4885KMT2A 760/4885IDO1 2744/4885
US-20100151002-A1 Guggulphospholipid Methods and Compositions SGMS2, SGMS1, PLA2G5 TSHR 3804/4885KMT2A 3338/4885IDO1 4837/4885
US-20050266068-A1 Cardiolipin molecules and methods of synthesis PHOSPHO1, MGLL, LIPA TSHR 3675/4885KMT2A 4521/4885IDO1 4327/4885
US-20170210775-A1 GUGGULPHOSPHOLIPID METHODS AND COMPOSITIONS SGMS1, SGMS2, GGPS1 TSHR 3366/4885KMT2A 3396/4885IDO1 4848/4885
US-20100035976-A1 Method of treating a tumor or a viral disease by administering a 2' , 5' -oligoadenylate analog ADAR, NSUN2, ADORA3 TSHR 1214/4885KMT2A 1131/4885IDO1 1401/4885
US-20100323000-A1 METHOD AND PROCESS FOR PREPARING CARDIOLIPIN PHOSPHO1, SGMS1, SGMS2 TSHR 2133/4885KMT2A 3936/4885IDO1 2732/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.